ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
GlaxoSmithKline has reached an agreement in principle with the U.S. government to resolve multiple investigations into company compliance, marketing, and selling practices. The $3 billion settlement will conclude an investigation into GSK’s marketing practices begun in 2004 by the U.S. Attorney’s Office in Colorado; the Department of Justice’s investigation of inappropriate use of a Medicaid rebate; and Justice’s probe into the marketing of the diabetes drug Avandia. “This is a significant step toward resolving difficult, long-standing matters which do not reflect the company that we are today,” says GSK CEO Andrew Witty.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter